Hanting Liang

Hanting Liang

Auto-generated profile, based on publicly available information

Hanting Liang

Department of Endocrinology, Key Laboratory of Endocrinology, National Commission of Health, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College 1

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2022 in Journal of Orthopaedic Translation
Verified
Journal Article
Open access
HLHanting Liang
Hanting Liang
OWOu Wang
Ou Wang
ZCZhifeng Cheng
Zhifeng Cheng
PXPeijin Xia
Peijin Xia
LWLiang Wang
Liang Wang
WXWeibo Xia
Weibo Xia
To investigate the effectiveness of a Chinese patent medicine, Jintiange capsules with the main component of artificial tiger bone powder, combined with alfacalcidol on muscle strength and balance of the lower extremities in patients with primary osteoporosis. A randomized, double-blind, double-dummy, positive-controlled, multicenter clinical trial. A total of 400 patients diagnosed with primary osteoporosis or osteopenia were recruited and randomized into the Jintiange or control groups. During the 52-week treatment, the participants in the Jintiange group were treated with Jintiange capsules (1.2 ​g each time, 3 times per day) and calcium carbonate simulant, while those in the control group were treated with calcium carbonate (element calcium 0.3 ​g, twice a day) and a Jintiange capsule simulant. Alfacalcidol (0.25 ​μg/d) was applied in both groups. The timed up and go test (TUG), chair rising test (CRT), and tandem gait test (TGT) were performed to evaluate balance, muscle strength and fall risk of the participants. There were 154 participants in the Jintiange group, and 157 participants in the control group were included in the per-protocol set. Comparing the data at week 52 from those at baseline, the TUG time decreased from 9.60 ​± ​2.25 ​s to 8.53 ​± ​2.06 ​s (p ​< ​0.001) in the Jintiange group and decreased from 9.50 ​± ​1.91 ​s to 9.11 ​± ​1.95 ​s (p ​< ​0.001) in the control group; the CRT time decreased from 11.49 ​± ​4.05 ​s to 8.57 ​± ​2.13 ​s (p ​< ​0.001) and 11.17 ​± ​3.21 ​s to 9.74 ​± ​1.98 ​s (p ​< ​0.001) in the Jintiange and control groups, respectively; the number of correct steps in the TGT increased significantly in both the control (7.40 ​± ​1.27 vs. 7.69 ​± ​0.87, p ​< ​0.01) and Jintiange groups (7.21 ​± ​1.58 vs. 7.60 ​± ​1.12, p ​< ​0.001). At the end of the study, the TUG and CRT results in the Jintiange group were superior to those in the control group (all p value ​< ​0.05), while no obvious difference was found in the TGT between the two groups. At week 52, the high fall risk proportions in the Jintiange group were significantly lower than those in the control group according to TUG (3.25% vs. 9.55%, p ​= ​0.023) and CRT (20.78% vs. 33.76%, p ​= ​0.01). Jintiange capsules combined with alfacalcidol can effectively improve muscle strength and the balance of the lower extremities and reduce fall risk in patients with primary osteoporosis/osteopenia. Artificial tiger bone powder, a traditional Chinese patent medicine, can improve muscle strength and balance and reduce fall risks effectively among patients with primary osteoporosis. It might be a therapeutic option for osteoporosis individuals combined with sarcopenia to improve their muscle function.

28 October 2021 in Calcified Tissue International
Verified
Journal Article
Closed access
PDF file
HLHanting Liang
Hanting Liang
YHYanfang Hou
Yanfang Hou
QPQianqian Pang
Qianqian Pang
YJYan Jiang
Yan Jiang
OWOu Wang
Ou Wang
WXWeibo Xia
Weibo Xia

7 May 2025 in Endocrine Connections
Verified
Journal Article
Open access
PDF file
HLHanting Liang
Hanting Liang
WQWenting Qi
Wenting Qi
CJChenxi Jin
Chenxi Jin
CZCong Zhang
Cong Zhang
YWYushuo Wu
Yushuo Wu
WXWeibo Xia
Weibo Xia
Objective: Short stature is a characteristic of X-linked hypophosphatemia (XLH). We aim to explore the factors that influence the height of pre-pubertal children with XLH. Methods: Based on a randomized clinical trial of high/low doses of active vitamin D with neutral phosphate treatment for XLH children, we recruited 124 pre-pubertal children with XLH, and 46 participants completed the 24-month follow-up. Participants were separated into the short stature (height Z score < −2) and non-short stature groups (height Z score ≥ −2). Height, medication history, biochemical parameters, the Thacher Rickets Severity Score (RSS), and bone age were evaluated. Results: At baseline, 50.8% of participants were short stature. The height Z score of males (−2.35 ± 1.18) was significantly lower than that of females (−1.86 ± 1.03), P = 0.014. The height Z score had negative correlations with age when enrolled, initial age of medication, and RSS (β: −0.327∼−0.251, P < 0.01), but had a positive correlation with calcium-phosphorus product (β: 0.213, P = 0.015). Compared to the non-short stature group, the proportion of delayed bone age was higher in the short stature group (10.0 vs 42.9%, P < 0.001). At the 24-month follow-up, the median height Z score increased from −1.91 to −1.74 (P = 0.002), whose improvement had no significant differences between groups of male/female, high/low doses of calcitriol, and non-truncating/truncating variants. Conclusion: In pre-pubertal children with XLH, a higher height Z score has associations with females, early initiation of treatment, better bone mineralization, and milder rachitic lesions. Conventional therapy improves their heights, but the efficacy does not depend on sex, active vitamin D dosage, or variant type.